Amr Radwan

781 total citations · 1 hit paper
42 papers, 474 citations indexed

About

Amr Radwan is a scholar working on Physiology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Amr Radwan has authored 42 papers receiving a total of 474 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Physiology, 19 papers in Surgery and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Amr Radwan's work include Asthma and respiratory diseases (27 papers), Eosinophilic Esophagitis (16 papers) and Allergic Rhinitis and Sensitization (12 papers). Amr Radwan is often cited by papers focused on Asthma and respiratory diseases (27 papers), Eosinophilic Esophagitis (16 papers) and Allergic Rhinitis and Sensitization (12 papers). Amr Radwan collaborates with scholars based in United States, United Kingdom and France. Amr Radwan's co-authors include Yamo Deniz, Paul J. Rowe, Juby A. Jacob‐Nara, Benjamin Ortiz, Leda Mannent, Elizabeth Laws, Nadia Daizadeh, Michael E. Wechsler, Faisal A. Khokhar and Robert R. Johnson and has published in prestigious journals such as Gastroenterology, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Amr Radwan

35 papers receiving 463 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis

2022 146 citations Michael E. Wechsler, Amr Radwan et al. The Journal of Allergy and Clinical Immunology In Practice profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Amr Radwan United States	11	283	168	156	124	86	42	474
Juby A. Jacob‐Nara United States	14	548 1.9×	246 1.5×	327 2.1×	240 1.9×	191 2.2×	112	801
Paul J. Rowe United States	14	613 2.2×	329 2.0×	282 1.8×	202 1.6×	186 2.2×	79	875
Jantina C. de Groot Netherlands	6	505 1.8×	368 2.2×	123 0.8×	28 0.2×	108 1.3×	7	553
Sarowar Golam Sweden	9	344 1.2×	261 1.6×	67 0.4×	10 0.1×	75 0.9×	14	392
Roberto Castaño Canada	12	152 0.5×	75 0.4×	152 1.0×	153 1.2×	84 1.0×	26	476
Laurence Gozalo United States	6	262 0.9×	262 1.6×	40 0.3×	7 0.1×	51 0.6×	14	351
Luigi Zucchi Italy	11	283 1.0×	234 1.4×	90 0.6×	4 0.0×	59 0.7×	27	374
K. Surrey United Kingdom	4	1.1k 3.9×	816 4.9×	646 4.1×	11 0.1×	76 0.9×	9	1.2k
Andrej A. Petrov United States	11	199 0.7×	181 1.1×	61 0.4×	2 0.0×	29 0.3×	39	345
Joachim Veith United States	4	172 0.6×	72 0.4×	142 0.9×	6 0.0×	64 0.7×	6	651

Countries citing papers authored by Amr Radwan

Since Specialization

Citations

This map shows the geographic impact of Amr Radwan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amr Radwan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amr Radwan more than expected).

Fields of papers citing papers by Amr Radwan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amr Radwan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amr Radwan. The network helps show where Amr Radwan may publish in the future.

Co-authorship network of co-authors of Amr Radwan

This figure shows the co-authorship network connecting the top 25 collaborators of Amr Radwan. A scholar is included among the top collaborators of Amr Radwan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amr Radwan. Amr Radwan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Celli, Bartolomé R., Klaus F. Rabe, Maarten van den Berge, et al.. (2025). Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy. American Journal of Respiratory and Critical Care Medicine. 211(5). 729–736. 5 indexed citations

Bredenoord, Albert J., Evan S. Dellon, Christoph Schlag, et al.. (2025). Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trial. Expert Review of Gastroenterology & Hepatology. 19(2). 197–209.

Fujieda, Shigeharu, Jayant M. Pinto, David W. Jang, et al.. (2025). Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registry. American Journal of Otolaryngology. 46(2). 104596–104596.

Muir, Amanda B., Alain Benitez, Ignacio de la Torre, et al.. (2025). Efficacy of Dupilumab on Facilitated Food Reintroduction in Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology.

Peters, Anju T., Jayant M. Pinto, Kathleen M. Buchheit, et al.. (2025). The burden of systemic corticosteroids in patients with chronic rhinosinusitis with nasal polyps. Allergy and Asthma Proceedings. 46(5). 406–413.

Dellon, Evan S., Ikuo Hirano, Mark Chehade, et al.. (2024). A206 DUPILUMAB TREATMENT REDUCES THE FREQUENCY OF DYSPHAGIA DAYS AND ACTIONS TO RELIEVE DYSPHAGIA IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS (EOE): RESULTS FROM THE PHASE 3 LIBERTY EOE TREET STUDY. Journal of the Canadian Association of Gastroenterology. 7(Supplement_1). 162–163.

Guilbert, Theresa W., Kevin R. Murphy, Eckard Hamelmann, et al.. (2024). Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study. Journal of Asthma and Allergy. Volume 17. 81–87. 2 indexed citations

Pavord, Ian, Klaus F. Rabe, Elliot Israel, et al.. (2024). Dupilumab Induces Long-Term On-Treatment Clinical Remission in Patients With Type 2 Asthma. The Journal of Allergy and Clinical Immunology In Practice. 13(1). 132–142. 15 indexed citations

Máspero, Jorge, Martti Antila, A. Deschildre, et al.. (2024). Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE). The Journal of Allergy and Clinical Immunology In Practice. 12(12). 3303–3312. 3 indexed citations

10.

Domingo, Christian, Klaus F. Rabe, David Price, et al.. (2023). Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose. ERJ Open Research. 9(6). 56–2023. 4 indexed citations

11.

Rabe, Klaus F., Ian Pavord, William W. Busse, et al.. (2023). Dupilumab improves long‐term outcomes in patients with uncontrolled, moderate‐to‐severe GINA‐based type 2 asthma, irrespective of allergic status. Allergy. 78(8). 2148–2156. 6 indexed citations

12.

Máspero, Jorge, Shirin Shafazand, Jeremy Cole, et al.. (2023). Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma. Respiratory Medicine. 218. 107344–107344. 2 indexed citations

13.

Hopkins, Claire, Joaquim Mullol, Asif Khan, et al.. (2023). Impact of Dupilumab on Sinonasal Symptoms and Outcomes in Severe Chronic Rhinosinusitis With Nasal Polyps. Otolaryngology. 170(4). 1173–1182. 4 indexed citations

14.

Pavord, Ian, Arnaud Bourdin, Alberto Papi, et al.. (2023). Dupilumab sustains efficacy in patients with moderate‐to‐severe type 2 asthma regardless of inhaled corticosteroids dose. Allergy. 78(11). 2921–2932. 6 indexed citations

15.

Corren, Jonathan, David J. Jackson, Thomas B. Casale, et al.. (2023). Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization. Journal of Asthma and Allergy. Volume 16. 249–260. 4 indexed citations

16.

Collins, Margaret H., Evan S. Dellon, Seema S. Aceves, et al.. (2023). Sa1274 DUPILUMAB REDUCED EOSINOPHIL COUNTS AND IMPROVED HSS GRADE AND STAGE SCORES IN PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: LIBERTY-EOE-TREET PHASE 3 STUDY PARTS A AND B. Gastroenterology. 164(6). S–347. 1 indexed citations

17.

Corren, Jonathan, Constance H. Katelaris, Mario Castro, et al.. (2023). Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma. ERJ Open Research. 9(5). 37–2023. 2 indexed citations

18.

Haddad, Anthony, Maria Domenica Cappellini, Alessia Marcon, et al.. (2014). Priapism, an Emerging Complication in β-Thalassemia Intermedia Patients. Hemoglobin. 38(5). 351–354. 5 indexed citations

19.

Price, David, et al.. (2013). A UK-Based Cost-Utility Analysis of Indacaterol, A Once-Daily Maintenance Bronchodilator for Patients with COPD, Using Real World Evidence on Resource Use. Applied Health Economics and Health Policy. 11(3). 259–274. 24 indexed citations

20.

Barnes, Neil & Amr Radwan. (2011). The APEX study: Retrospective review of oral corticosteroid use in omalizumab-treated severe allergic asthma patients in UK clinical practice. European Respiratory Journal. 38(Suppl 55). p269–p269. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact